Side Effects of vorapaxar: A Synthesis of Findings from 5 Studies

  1. Home
  2. Side Effects of vorapaxar
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of vorapaxar: A Synthesis of Findings from 5 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of vorapaxar: A Synthesis of Findings from 5 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Vorapaxar is a novel drug that inhibits protease-activated receptor-1 (PAR-1), a key player in platelet activation, which is crucial for both acute and chronic atherothrombotic events. 3 highlights the potential of vorapaxar to prevent these events by controlling platelet activity. 4 focuses on the safety and tolerability of SCH 530348, an oral PAR-1 inhibitor, in patients undergoing percutaneous coronary intervention (PCI), finding it to be well-tolerated.

Reasons for Side Effects

Vorapaxar functions by inhibiting platelet activation, resulting in thinner blood. This mechanism, while beneficial in preventing blood clots, can increase the risk of bleeding. Additionally, interactions with other medications may occur.

Common Side Effects

Bleeding

The most common side effect associated with vorapaxar is bleeding. This arises from its ability to suppress platelet clotting. 3 underscores this mechanism by emphasizing vorapaxar's role in inhibiting platelet activation and reactivity.

Gastrointestinal side effects

Vorapaxar can also cause gastrointestinal side effects due to its potential to irritate the stomach lining.

Allergic reactions

Allergic reactions to vorapaxar are possible because it can trigger an immune response within the body.

Countermeasures for Side Effects

Bleeding

Patients taking vorapaxar should avoid medications that could contribute to bleeding. Regular medical checkups to monitor for signs of bleeding are also recommended.

Gastrointestinal side effects

Maintaining regular meal times and consuming food slowly can help mitigate gastrointestinal side effects. Additionally, medications designed to protect the stomach lining may be prescribed.

Allergic reactions

Immediate medical attention is crucial if an allergic reaction occurs.

Comparison of Studies

Common Points of Studies

The shared objective of these studies is to assess the safety and effectiveness of vorapaxar.

Differences in Studies

3 focuses on the potential of vorapaxar to prevent atherothrombotic events by inhibiting platelet activation. 4 concentrates on the safety and tolerability of an oral PAR-1 inhibitor (SCH 530348) in patients undergoing PCI.

Precautions for Applying to Real Life

Due to the potential for bleeding, it's essential to follow your doctor's instructions when taking vorapaxar. Avoid medications that might increase the risk of bleeding.

Limitations of Current Research

Research on vorapaxar is still in its early stages. Further investigation is required to understand the long-term safety and effectiveness of this drug.

Future Research Directions

Future research should focus on assessing the long-term safety and efficacy of vorapaxar. Additionally, exploring ways to mitigate the side effects of this drug is a crucial area for investigation.

Conclusion

Vorapaxar is a promising drug for preventing blood clots by thinning blood. However, it comes with the risk of increased bleeding. It's essential to be aware of this risk, follow your doctor's guidance, and monitor for any signs of bleeding.

Literature analysis of 5 papers
Positive Content
5
Neutral Content
0
Negative Content
0
Article Type
1
2
2
3
5
1.

Vigabatrin for refractory partial epilepsy.

Author: HemmingKarla, MaguireMelissa J, HuttonJane L, MarsonAnthony G

Epilepsy treatment
Visual field constriction

Vigabatrin, an antiepileptic drug for refractory epilepsy, is generally well-tolerated. However, long-term use has been associated with asymptomatic visual field constriction, highlighting the need for monitoring during treatment.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

2.

Vigabatrin for refractory partial epilepsy.

Author: HemmingKarla, MaguireMelissa J, HuttonJane L, MarsonAnthony G

Refractory epilepsy treatment
Visual field constriction

Vigabatrin is an antiepileptic drug that is used for the treatment of refractory epilepsy. Although vigabatrin is generally well tolerated, it can cause asymptomatic visual field constriction.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

3.

Vorapaxar: a novel protease-activated receptor-1 inhibitor.

Author: GurbelPaul A, JeongYoung-Hoon, TantryUdaya S

Antithrombotic efficacy
Hepatic toxicity
Intracranial hemorrhage

PAR-1 inhibitors may provide additional benefits in attenuating ischemic event occurrence in selected patients. However, their effectiveness as an antithrombotic agent and their side effects are major concerns. Future large-scale trials are needed to define their specific role.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

4.

Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study.

Author: BeckerRichard C, MoliternoDavid J, JenningsLisa K, PieperKaren S, PeiJinglan, NiedermanAlan, ZiadaKhaled M, BermanGail, StronyJohn, JosephDiane, MahaffeyKenneth W, Van de WerfFrans, VeltriEnrico, HarringtonRobert A,

Reduced bleeding
Well tolerated
None reported

Oral SCH 530348 was generally well tolerated and did not cause increased TIMI bleeding.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

Molormer: a lightweight self-attention-based method focused on spatial structure of molecular graph for drug-drug interactions prediction.

Author: ZhangXudong, WangGan, MengXiangyu, WangShuang, ZhangYing, Rodriguez-PatonAlfonso, WangJianmin, WangXun

Drug-drug interaction prediction

Molormer is a method for predicting drug-drug interactions (DDIs) that uses a lightweight attention mechanism to encode the 2D structures of drugs. This method outperforms existing methods by accurately and rapidly identifying DDIs and enhancing the effectiveness of combination therapy while avoiding unintended side effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.